Sino Biological is a world-leading manufacturer of recombinant protein and antibody reagents for life science researches and drug discoveries. In response to the current COVID-19 pandemic, we have developed a series of active reagents (virus proteins, antibodies, and pseudoviruses) to facilitate serologic tests and anti-viral drug developments.
Danish Galecto Inc. secures US$64m equity financing
Latest NewsDanish fibrosis and cancer specialist Galecto Inc. has raised US$64m in a Series B round led by Soleus Capital.
MosaMeat NV bags US$55m financing
Latest NewsMaastricht-based cultured meat producer Mosa Meat NV has raised $55m in a Series B financing, bringing its funding to $63.8m.
Green carbon footprint
OpinionIn September, Unilever announced a €1bn investment to improve the sustainability of its cleaning brands from the ground up. European Biotechnology spoke to Dr Neil Parry, R&D programme director of biotechnology and biosourcing at Unilever about the goals of Clean Future.
A Comprehensive Tool Set for COVID-19 Research
Sponsored PublicationsSino Biological is a world-leading manufacturer of recombinant protein and antibody reagents for life science researches and drug discoveries. In response to the current COVID-19 pandemic, we have developed a series of active reagents (virus proteins, antibodies, and pseudoviruses) to facilitate serologic tests and anti-viral drug developments.
New on Vifor Pharma board
AppointmentsSince September Gregory Oakes is a new Member of the Vifor Management Board and President North America of the Swiss pharmaceutical company.
Pureos Bioventures closes US$170m fund
Latest NewsNewly formed venture capitalist Pureos Bioventures has set up a US$170m fund dedicated to Swiss and European drug developers.
Biotechs request money for COVID therapeutics
Latest NewsGerman biotech companies and their industry association BIO Deutschland have called for appropriate investments into clinical COVID-19 therapies.
Complete toolkit for SARS-CoV-2 antigen test
ProductsSino Biological Inc. has developed a complete toolkit for SARS-CoV-2 antigen tests, including a large panel of antibodies specific to SARS-CoV-2 S&N proteins and antibody pairs that can be used to assemble detection assays for the corresponding antigen.
Polyneuron Pharmaceuticals AG extends Series A financing
Latest NewsSwiss auto-immunity specialist Polyneuron Pharmaceuticals AG has received CHF14m from HBM Healthcare Investments.
Amarna Therapeutics appointed new CEO
AppointmentsDutch Amarna Therapeutics has appointed Dr Steen Klysner. The new CEO has been active in the biotech industry for more than 30 years